Genzyme's Osteoarthritis Sales Force Expands With Buyback Of Synvisc Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
The company acquires sales and marketing rights for the knee osteoarthritis agent from Wyeth; Genzyme previously held only manufacturing rights. The company plans to offer employment to Wyeth's 95 Synvisc sales reps and 10 district managers, almost quadrupling the size of Genzyme's own 36-rep force for the product.